Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | Director | January 22, 2025 | January 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allarity Therapeutics, Inc.
Report date January 22, 2025 · Filed January 25, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2035-01-22 | Direct | 25,000 |
Reported balance
After 2025-01-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-01-22 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2025 Filed Jan 25, 2025 01:09 UTC Amendment | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-25-001852 · rdgdoc.xml · derivative · entry 1 Benjamin Laura · CIK 0001990896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-22 F1 · derivative.exercise_date: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-25-001793 · rdgdoc.xml · derivative · entry 1 Benjamin Laura · CIK 0001990896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.